Clinical trial
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
NCT00461630 · University of Oxford, Other · Completed
Key facts
| NCT number | NCT00461630 |
|---|---|
| Title | Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE |
| Official title | A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant |
| Acronym | HPS2-THRIVE |
| Lead sponsor | University of Oxford, Other |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus, Coronary Heart Disease |
| Intervention type | Drug |
| Interventions | ER niacin/laropiprant, simvastatin, ezetimibe/simvastatin |
| Enrollment | 25,673 |
| Start date | Jan 1, 2007 |
| Primary completion | Oct 1, 2012 |
| Completion | Oct 1, 2012 |
| First posted | Apr 18, 2007 |
| Last update posted | Feb 28, 2014 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: